Circular RNAs Variously Participate in Coronary Atherogenesis
Liudmila V Dergunova1, Margarita A Vinogradina1, Ivan B Filippenkov1
1Laboratory of Human Molecular Genetics, National Research Center "Kurchatov Institute", Kurchatov Sq. 2, Moscow 123182, Russia.
Current Issues in Molecular Biology
|August 25, 2023
Summary
Circular RNAs (circRNAs) are key regulators in coronary artery disease (CAD) pathogenesis. Specific circRNAs show atheroprotective or proatherogenic effects, offering potential as biomarkers and therapeutic targets for cardiovascular diseases.
Area of Science:
- Molecular Biology
- Genetics
- Cardiovascular Research
Background:
- Circular RNAs (circRNAs) are non-coding RNAs crucial in cardiovascular diseases.
- They regulate gene expression post-transcriptionally via miRNA-mRNA interactions.
- circRNAs are implicated in the pathogenesis of various heart conditions, including atherosclerosis.
Purpose of the Study:
- To review the role of circRNAs in coronary artery disease (CAD) pathogenesis.
- To update information on atherogenesis-related circRNAs.
- To discuss circRNA detection, interactions, and therapeutic potential.
Main Methods:
- Literature review of studies on circRNAs in CAD.
- Analysis of circRNA-miRNA-mRNA regulatory networks.
- Discussion of current detection and therapeutic strategies.
Main Results:
- Specific circRNAs exhibit atheroprotective (e.g., circ_0001445) or proatherogenic (e.g., circ_0002984) effects in CAD.
- circRNAs are involved in regulatory axes crucial for cardiovascular health.
- High stability makes circRNAs promising biomarkers.
Conclusions:
- circRNAs are significant players in coronary artery atherogenesis.
- They represent potential diagnostic biomarkers and therapeutic targets for CAD.
- Further research into circRNA-based interventions is warranted.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
02:15Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
01:23RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K